Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

Journal of Clinical Oncology

Volumn 18, Issue 8, 2000, Pages 1614-1621

  Spitler, Lynn E ^a   Grossbard, Michael L ^a   Ernstoff, Marc S ^a   Silver, Gary ^a   Jacobs, Mark ^a   Ann Hayes, F ^a   Soong, Seng Jaw ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MELANOMA; PRIORITY JOURNAL; SKIN IRRITATION; TREATMENT INDICATION;

EID: 0033998594     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.8.1614     Document Type: Article

References (40)

1. Brand CU, Ellwanger U, Stroebel W, et al: Prolonged survival of 2 years or longer for patients with disseminated melanoma: An analysis of related prognostic factors. Cancer 79:2345-2353, 1997
2. Garbe C, Buttner P, Bertz J, et al: Primary cutaneous melanoma: Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 75:2484-2491, 1995
3. Tafra L, Dale PS, Wanek LA, et al: Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 110:119-128, 1995
4. Overett TK, Shiu MH: Surgical treatment of distant metastatic melanoma: Indications and results. Cancer 56:1222-1230, 1985
5. Hena MA, Emrich LJ, Nambisan RN, et al: Effect of surgical treatment on stage IV melanoma. Am J Surg 153:270-275, 1987
6. Karp NS, Boyd A, DePan HJ, et al: Thoracotomy for metastatic malignant melanoma of the lung. Surgery 107:256-261, 1990
7. Karakousis CP, Velez A, Driscoll DL, et al: Metastasectomy in malignant melanoma. Surgery 115:295-302, 1994
8. Hsueh EC, Nizze A, Essner R, et al: Adjuvant immunotherapy with polyvalent melanoma cell vaccine (PMCV) prolongs survival after complete resection of distant melanoma metastases: matched pair analysis. Proc Am Soc Clin Oncol 16:492a, 1997 (abstr 1772a)
9. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684 [see comments]. J Clin Oncol 14:7-17, 1996
10. Grabstein KH, Urdal DL, Tushinski RJ, et al: Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232:506-508, 1986
11. Thomassen MJ, Barna BP, Rankin D, et al: Differential effect of recombinant granulocyte macrophage colony-stimulating factor on human monocytes and alveolar macrophages. Cancer Res 49:4086-4089, 1989
12. Wing EJ, Magee DM, Whiteside TL, et al: Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. Blood 73:643-646, 1989
13. Chachoua A, Oratz R, Hoogmoed R, et al: Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor. J Immunother Emphasis Tumor Immunol 15:217-224, 1994
14. Young JW, Szabolcs P, Moore MA: Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha [published erratum appears in J Exp Med 183:1283, 1996]. J Exp Med 182:1111-1119, 1995
15. Szabolcs P, Moore MA, Young JW: Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J Immunol 154:5851-5861, 1995
16. Szabolcs P, Avigan D, Gezelter S, et al: Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate. Blood 87:4520-4530, 1996
17. Kumar R, Dong Z, Fidler IJ: Differential regulation of metalloelastase activity in murine peritoneal macrophages by granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor. J Immunol 157:5104-5111, 1996
18. Dong Z, Kumar R, Yang X, et al: Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88:801-810, 1997
19. Balch CM, Soong SJ, Murad TM, et al: A multifactorial analysis of melanoma: IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1:126-134, 1983
20. Balch CM, Soong SJ, Murad TM, et al: A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 193:377-388, 1981
21. Morton DL, Foshag LJ, Hoon DS, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine [published erratum appears in Ann Surg 217:309, 1993]. Ann Surg 216:463-482, 1992
22. Feun LG, Gutterman J, Burgess MA, et al: The natural history of resectable metastatic melanoma (stage IVA melanoma). Cancer 50: 1656-1663, 1982
23. Saxman SB, Meyers ML, Chapman PB, et al: A phase III multicenter randomized trial of DTIC, cisplatin, BCNU and tamoxifen versus DTIC alone in patients with metastatic melanoma. Proc Am Soc Clin Oncol 18:536a, 1999 (abstr 2068)
24. Legha SS: Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with Interferon alpha and chemotherapy. Semin Oncol 24:539-43, 1997
25. Legha SS, Ring S, Eton O, et al: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, Interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16:1752-1759, 1998
26. Richards JM, Mehta N, Ramming K, et al: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10:1338-1343, 1992
27. Richards JM, Gale D, Mehta N, et al: Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 17:651-657, 1999
28. Hsueh EC, Gupta RK, Qi K, et al: Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 16:2913-2920, 1998
29. Bugelski PJ, Kirsh RL, Poste G: New histochemical method for measuring intratumoral macrophages and macrophage recruitment into experimental metastases. Cancer Res 43:5493-5501, 1983
30. Bugelski PJ, Kirsh RL, Sowinski JM, et al: Changes in the macrophage content of lung metastases at different stages in tumor growth. Am J Pathol 118:419-424, 1985
31. Bugelski PJ, Corwin SP, North SM, et al: Macrophage content of spontaneous metastases at different stages of growth. Cancer Res 47:4141-4145, 1937
32. Kirkwood JM, Ibrahim J, Sondak V, et al: Role of high-dose IFN in high-risk melanoma: Preliminary results of the E1690/S9111/ C9190 US intergroup postoperative adjuvant trial of high and low-dose IFNalpha2b (HDI and LDI) in resected high-risk primary or regionally lymph node metastatic melanoma in relation to 10-year updated results of E1684, Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B, 1999. Http://ecog.dfci.harvard.edn/∼ecogdba/general/e 1690_abstract.html
33. Grob JJ, Dreno B, Delaunay M, et al: Long-term results of adjuvant therapy with low dose IFN-gamma 2A in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases. Proc Am Soc Clin Oncol 17:514a, 1998 (abstr 1983a)
34. Quirt IC, Shelley WE, Pater JL, et al: Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: A phase III study by the National Cancer Institute of Canada Clinical Trials Group [see comments]. J Clin Oncol 9:729-735, 1991
35. Spitler LE: A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 9:736-740, 1991
36. Wallack MK, Sivanandham M, Balch CM, et al: A phase III randomized, double-blind multi-institutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 75:34-42, 1995
37. Livingston PO, Wong GYC, Adluri S, et al: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994
38. Bystryn JC, Oratz R, Roses D, et al: Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 69:1157-1164, 1992
39. Berd D, Maguire HCJ, Schuchter LM, et al: Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases, J Clin Oncol 15:2359-2370, 1997
40. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma [see comments]. Nat Med 4:321-327, 1998